Overview

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

Status:
Completed

Trial end date:
2023-11-28

Target enrollment:

Participant gender:

Summary

The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Treatments:

Digoxin
Midazolam
Repaglinide
Rosuvastatin Calcium